MedTrace Logo

Capillary Dysfunction and CD46-immunoreceptor (CD46) Type in MS

NCT03906370 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2023-05-11

No results posted yet for this study

Summary

This project aims to contribute knowledge to early MS disease mechanisms at the brain-blood interface using a combined immunological and neuroimaging approach.

The aim is to provide a novel vascular model to assess MS disease activity, and to explore its potential as an early diagnostic biomarker, prior to blood-brain barrier disruption. Additionally, the investigators want to investigate influence of immune receptor defects upon disease activity and MS brain vascular system. These aims are addressed by investigating immune receptor signals and vascular imaging modalities acquired in newly diagnosed untreated MS cohort, followed at our institution.

Conditions

Interventions

DIAGNOSTIC_TEST

Diagnostic criteria for MS

The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Linda Sundvall, MD · Department of Neurology, Aarhus University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2021-05-01
Completion
2021-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03906370 on ClinicalTrials.gov